These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 28592657)

  • 1. Induced pluripotent stem cell models of lysosomal storage disorders.
    Borger DK; McMahon B; Roshan Lal T; Serra-Vinardell J; Aflaki E; Sidransky E
    Dis Model Mech; 2017 Jun; 10(6):691-704. PubMed ID: 28592657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling neuronopathic storage diseases with patient-derived culture systems.
    Zunke F; Mazzulli JR
    Neurobiol Dis; 2019 Jul; 127():147-162. PubMed ID: 30790616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of induced pluripotent stem cells in lysosomal storage diseases.
    Kido J; Nakamura K; Era T
    Mol Cell Neurosci; 2020 Oct; 108():103540. PubMed ID: 32828964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: A nationwide survey in Japan.
    Koto Y; Sakai N; Lee Y; Kakee N; Matsuda J; Tsuboi K; Shimozawa N; Okuyama T; Nakamura K; Narita A; Kobayashi H; Uehara R; Nakamura Y; Kato K; Eto Y
    Mol Genet Metab; 2021 Jul; 133(3):277-288. PubMed ID: 34090759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic convergence of Parkinson's disease and lysosomal storage disorders.
    Deng H; Xiu X; Jankovic J
    Mol Neurobiol; 2015; 51(3):1554-68. PubMed ID: 25099932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges.
    Poon A; Zhang Y; Chandrasekaran A; Phanthong P; Schmid B; Nielsen TT; Freude KK
    N Biotechnol; 2017 Oct; 39(Pt B):190-198. PubMed ID: 28579476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases.
    Huang HP; Chuang CY; Kuo HC
    Stem Cell Res Ther; 2012 Aug; 3(4):34. PubMed ID: 22925465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gaucher disease and other storage disorders.
    Grabowski GA
    Hematology Am Soc Hematol Educ Program; 2012; 2012():13-8. PubMed ID: 23233555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding newborn screening for lysosomal disorders: opportunities and challenges.
    Waggoner DJ; Tan CA
    Dev Disabil Res Rev; 2011; 17(1):9-14. PubMed ID: 22447749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The 20th European Study Group on Lysosomal Diseases Workshop "Lysosomal storage disorders: problems of neurodegeneration and new therapeutic avenues" (Napoli, Italy, 1-4 Oct. 2015)].
    Redaktsiia
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(5):125-129. PubMed ID: 27437549
    [No Abstract]   [Full Text] [Related]  

  • 12. Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease.
    Wu YY; Chiu FL; Yeh CS; Kuo HC
    Open Biol; 2019 Jan; 9(1):180177. PubMed ID: 30958120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newborn screening for lysosomal storage disorders.
    Nakamura K; Hattori K; Endo F
    Am J Med Genet C Semin Med Genet; 2011 Feb; 157C(1):63-71. PubMed ID: 21312327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for lysosomal storage disorders.
    Beck M
    IUBMB Life; 2010 Jan; 62(1):33-40. PubMed ID: 20014233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass spectrometry-based proteomics in neurodegenerative lysosomal storage disorders.
    Li W; Cologna SM
    Mol Omics; 2022 May; 18(4):256-278. PubMed ID: 35343995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysosomal storage disease overview.
    Sun A
    Ann Transl Med; 2018 Dec; 6(24):476. PubMed ID: 30740407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of infiltrating peripheral myeloid cells in the brains of mouse models of lysosomal storage disorders.
    Cho SM; Vardi A; Platt N; Futerman AH
    J Neurochem; 2019 Mar; 148(5):625-638. PubMed ID: 29900534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactosylceramide in lysosomal storage disorders: a comparative immunohistochemical and biochemical study.
    Hůlková H; Ledvinová J; Asfaw B; Koubek K; Kopriva K; Elleder M
    Virchows Arch; 2005 Jul; 447(1):31-44. PubMed ID: 15918012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced Pluripotent Stem Cells Derived from a CLN5 Patient Manifest Phenotypic Characteristics of Neuronal Ceroid Lipofuscinoses.
    Uusi-Rauva K; Blom T; von Schantz-Fant C; Blom T; Jalanko A; Kyttälä A
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28468312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-α-glucosidase in Pompe's iPSCs.
    Higuchi T; Kawagoe S; Otsu M; Shimada Y; Kobayashi H; Hirayama R; Eto K; Ida H; Ohashi T; Nakauchi H; Eto Y
    Mol Genet Metab; 2014 May; 112(1):44-8. PubMed ID: 24642446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.